Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,29976060,bioavailability,Pharmacokinetic studies in rats showed an increase in the bioavailability of peptide 12 > 70-fold (from 0.58 ± 0.11% to 43.8 ± 14.9%) after applying the LPCM method to peptide 12 and converting it to the prodrug 12P.,Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29976060/),%,0.58,1759,DB00583,L-Carnitine
,29976060,bioavailability,Pharmacokinetic studies in rats showed an increase in the bioavailability of peptide 12 > 70-fold (from 0.58 ± 0.11% to 43.8 ± 14.9%) after applying the LPCM method to peptide 12 and converting it to the prodrug 12P.,Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29976060/),%,43.8,1760,DB00583,L-Carnitine
,8971593,recovery,The recovery of the extraction procedure was in the range 82.6%-95.4% for all 3 compounds.,"Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracene. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971593/),%,82,6486,DB00583,L-Carnitine
,8971593,recovery,The recovery of the extraction procedure was in the range 82.6%-95.4% for all 3 compounds.,"Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracene. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971593/),%,95,6487,DB00583,L-Carnitine
,1550066,concentrations (SCAC),"A hamburger meal (345 mumol total carnitine) induced peak jejunal fluid free (unesterified) and short-chain acylcarnitine concentrations (SCAC) of 209 and 130 mumol/L, respectively.",The effect of enteral carnitine administration in humans. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1550066/),[μM] / [l],209,12173,DB00583,L-Carnitine
,1550066,concentrations (SCAC),"A hamburger meal (345 mumol total carnitine) induced peak jejunal fluid free (unesterified) and short-chain acylcarnitine concentrations (SCAC) of 209 and 130 mumol/L, respectively.",The effect of enteral carnitine administration in humans. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1550066/),[μM] / [l],130,12174,DB00583,L-Carnitine
,6716912,urinary,The mean urinary carnitine excretion per day was 163.5 mumol (range 63.7-419.6 mumol) in patients with intact renal function.,[Serum levels and urine excretion of L-carnitine in patients with normal and impaired kidney function]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716912/),μM,163.5,12735,DB00583,L-Carnitine
,6716912,elimination per,"Extreme impairment of glomerular filtration rate (creatinine clearance less than 20 ml/min) resulted in higher carnitine concentrations in serum (108.9 +/- 39.4 mumol/l, n = 18, p less than 0.05), lower carnitine elimination per day (78.5 mumol, range 14.5 - 424.3 mumol, n = 18, p less than 0.05) and a decreased carnitine clearance (0.8 ml/min, range 0.2 - 3.8 ml/min).",[Serum levels and urine excretion of L-carnitine in patients with normal and impaired kidney function]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716912/),μM,78.5,12736,DB00583,L-Carnitine
,6716912,clearance,"Extreme impairment of glomerular filtration rate (creatinine clearance less than 20 ml/min) resulted in higher carnitine concentrations in serum (108.9 +/- 39.4 mumol/l, n = 18, p less than 0.05), lower carnitine elimination per day (78.5 mumol, range 14.5 - 424.3 mumol, n = 18, p less than 0.05) and a decreased carnitine clearance (0.8 ml/min, range 0.2 - 3.8 ml/min).",[Serum levels and urine excretion of L-carnitine in patients with normal and impaired kidney function]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716912/),[ml] / [min],0.8,12737,DB00583,L-Carnitine
,12709724,net losses,"Urinary elimination of pivaloylcarnitine resulted in a marked increase in total carnitine excretion, as well as net losses of total carnitine of approximately 4.6 mmol with the 200-mg, 10-day regimen and up to 14.9 mmol with the 400-mg, 14-day regimen.",Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709724/),mM,4.6,13195,DB00583,L-Carnitine
up to,12709724,net losses,"Urinary elimination of pivaloylcarnitine resulted in a marked increase in total carnitine excretion, as well as net losses of total carnitine of approximately 4.6 mmol with the 200-mg, 10-day regimen and up to 14.9 mmol with the 400-mg, 14-day regimen.",Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709724/),mM,14.9,13196,DB00583,L-Carnitine
,16988826,AUC dose,"Plasma and urine concentrations of LC and ALC from 11 patients on carboplatin therapy (1 h intravenous infusion; AUC dose 4.8 +/- 1.1 mg/ml min) in combination with docetaxel, paclitaxel or vinorelbine, were determined by high-performance liquid chromatography with fluorimetric detection.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[mg] / [min·ml],4.8,24369,DB00583,L-Carnitine
,16988826,plasma concentrations,"Before carboplatin therapy, the mean +/- SD plasma concentrations of LC and ALC were 47.8 +/- 10.9 and 7.04 +/- 1.04 nmoles/ml, respectively, and remained constant throughout the entire study period.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[nmoles] / [ml],47.8,24370,DB00583,L-Carnitine
,16988826,plasma concentrations,"Before carboplatin therapy, the mean +/- SD plasma concentrations of LC and ALC were 47.8 +/- 10.9 and 7.04 +/- 1.04 nmoles/ml, respectively, and remained constant throughout the entire study period.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[nmoles] / [ml],7.04,24371,DB00583,L-Carnitine
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],115,24372,DB00583,L-Carnitine
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],480,24373,DB00583,L-Carnitine
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],41,24374,DB00583,L-Carnitine
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],89,24375,DB00583,L-Carnitine
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],1.67,24376,DB00583,L-Carnitine
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],9.05,24377,DB00583,L-Carnitine
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],4.02,24378,DB00583,L-Carnitine
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],7.97,24379,DB00583,L-Carnitine
,33156405,particle size,"For lipo-carnitine and nano-carnitine formulations, particle size values were 97.88 ± 2.96 nm and 250.90 ± 6.15 nm; polydispersity index values were 0.35 ± 0.01 and 0.22 ± 0.03; zeta potential values were 6.36 ± 0.54 mV and - 32.80 ± 2.26 mV; and encapsulation efficiency percentage values were 14.26 ± 3.52% and 21.93 ± 4.17%, respectively.",Polymeric Nanoparticle Versus Liposome Formulations: Comparative Physicochemical and Metabolomic Studies as L-Carnitine Delivery Systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33156405/),nm,97.88,27258,DB00583,L-Carnitine
,33156405,particle size,"For lipo-carnitine and nano-carnitine formulations, particle size values were 97.88 ± 2.96 nm and 250.90 ± 6.15 nm; polydispersity index values were 0.35 ± 0.01 and 0.22 ± 0.03; zeta potential values were 6.36 ± 0.54 mV and - 32.80 ± 2.26 mV; and encapsulation efficiency percentage values were 14.26 ± 3.52% and 21.93 ± 4.17%, respectively.",Polymeric Nanoparticle Versus Liposome Formulations: Comparative Physicochemical and Metabolomic Studies as L-Carnitine Delivery Systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33156405/),nm,250.90,27259,DB00583,L-Carnitine
,33156405,polydispersity index,"For lipo-carnitine and nano-carnitine formulations, particle size values were 97.88 ± 2.96 nm and 250.90 ± 6.15 nm; polydispersity index values were 0.35 ± 0.01 and 0.22 ± 0.03; zeta potential values were 6.36 ± 0.54 mV and - 32.80 ± 2.26 mV; and encapsulation efficiency percentage values were 14.26 ± 3.52% and 21.93 ± 4.17%, respectively.",Polymeric Nanoparticle Versus Liposome Formulations: Comparative Physicochemical and Metabolomic Studies as L-Carnitine Delivery Systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33156405/),,0.35,27260,DB00583,L-Carnitine
,33156405,polydispersity index,"For lipo-carnitine and nano-carnitine formulations, particle size values were 97.88 ± 2.96 nm and 250.90 ± 6.15 nm; polydispersity index values were 0.35 ± 0.01 and 0.22 ± 0.03; zeta potential values were 6.36 ± 0.54 mV and - 32.80 ± 2.26 mV; and encapsulation efficiency percentage values were 14.26 ± 3.52% and 21.93 ± 4.17%, respectively.",Polymeric Nanoparticle Versus Liposome Formulations: Comparative Physicochemical and Metabolomic Studies as L-Carnitine Delivery Systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33156405/),,0.22,27261,DB00583,L-Carnitine
,33156405,zeta potential,"For lipo-carnitine and nano-carnitine formulations, particle size values were 97.88 ± 2.96 nm and 250.90 ± 6.15 nm; polydispersity index values were 0.35 ± 0.01 and 0.22 ± 0.03; zeta potential values were 6.36 ± 0.54 mV and - 32.80 ± 2.26 mV; and encapsulation efficiency percentage values were 14.26 ± 3.52% and 21.93 ± 4.17%, respectively.",Polymeric Nanoparticle Versus Liposome Formulations: Comparative Physicochemical and Metabolomic Studies as L-Carnitine Delivery Systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33156405/),mv,6.36,27262,DB00583,L-Carnitine
,33156405,zeta potential,"For lipo-carnitine and nano-carnitine formulations, particle size values were 97.88 ± 2.96 nm and 250.90 ± 6.15 nm; polydispersity index values were 0.35 ± 0.01 and 0.22 ± 0.03; zeta potential values were 6.36 ± 0.54 mV and - 32.80 ± 2.26 mV; and encapsulation efficiency percentage values were 14.26 ± 3.52% and 21.93 ± 4.17%, respectively.",Polymeric Nanoparticle Versus Liposome Formulations: Comparative Physicochemical and Metabolomic Studies as L-Carnitine Delivery Systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33156405/),mv,- 32.80,27263,DB00583,L-Carnitine
,33156405,encapsulation efficiency percentage,"For lipo-carnitine and nano-carnitine formulations, particle size values were 97.88 ± 2.96 nm and 250.90 ± 6.15 nm; polydispersity index values were 0.35 ± 0.01 and 0.22 ± 0.03; zeta potential values were 6.36 ± 0.54 mV and - 32.80 ± 2.26 mV; and encapsulation efficiency percentage values were 14.26 ± 3.52% and 21.93 ± 4.17%, respectively.",Polymeric Nanoparticle Versus Liposome Formulations: Comparative Physicochemical and Metabolomic Studies as L-Carnitine Delivery Systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33156405/),%,14.26,27264,DB00583,L-Carnitine
,33156405,encapsulation efficiency percentage,"For lipo-carnitine and nano-carnitine formulations, particle size values were 97.88 ± 2.96 nm and 250.90 ± 6.15 nm; polydispersity index values were 0.35 ± 0.01 and 0.22 ± 0.03; zeta potential values were 6.36 ± 0.54 mV and - 32.80 ± 2.26 mV; and encapsulation efficiency percentage values were 14.26 ± 3.52% and 21.93 ± 4.17%, respectively.",Polymeric Nanoparticle Versus Liposome Formulations: Comparative Physicochemical and Metabolomic Studies as L-Carnitine Delivery Systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33156405/),%,21.93,27265,DB00583,L-Carnitine
,31683880,fractional excretion,"TMAO clearances were not significantly different from mGFR, with a mean ± SD TMAO fractional excretion of 105% ± 32%.",Elevation of Trimethylamine-N-Oxide in Chronic Kidney Disease: Contribution of Decreased Glomerular Filtration Rate. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31683880/),%,105,36284,DB00583,L-Carnitine
,9190838,half-life,PLC-CD3 in perfusate decreased in a monoexponential manner with a half-life of 90 +/- 24 min (S.D.) (10 microM) and 94 +/- 11 min (200 microM).,Excretion and metabolism of propionyl-L-carnitine in the isolated perfused rat kidney. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190838/),min,90,39894,DB00583,L-Carnitine
,9190838,half-life,PLC-CD3 in perfusate decreased in a monoexponential manner with a half-life of 90 +/- 24 min (S.D.) (10 microM) and 94 +/- 11 min (200 microM).,Excretion and metabolism of propionyl-L-carnitine in the isolated perfused rat kidney. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190838/),min,94,39895,DB00583,L-Carnitine
,9190838,re,"The renal excretory clearance of PLC-CD3 was significantly lower (P < .05, unpaired t test) at an initial concentration of 10 microM (45 +/- 23 microl/min) than at 200 microM (85 +/- 28 microl/min), but in both cases it was substantially less than the glomerular filtration rate, which indicates extensive tubular reabsorption.",Excretion and metabolism of propionyl-L-carnitine in the isolated perfused rat kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190838/),μ,85,39896,DB00583,L-Carnitine
,1961125,Urinary excretion,Urinary excretion of total carnitine was 16% to 23% of intake.,Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961125/),%,16,42653,DB00583,L-Carnitine
,1961125,Urinary excretion,Urinary excretion of total carnitine was 16% to 23% of intake.,Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1961125/),%,23,42654,DB00583,L-Carnitine
,15848954,apparent elimination half-life,PTZ was eliminated with the apparent elimination half-life of 13.0 min after microinjection into the parietal cortex area 2 region of the rat brain.,In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),min,13.0,53252,DB00583,L-Carnitine
,15848954,apparent efflux clearance,"The apparent efflux clearance of PTZ across the BBB was 137 microl/min/g brain, which was calculated from the elimination rate constant (5.35 x 10(-2) min(-1) and the distribution volume in the brain (2.56 ml/g brain).",In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),[μl] / [brain·g·min],137,53253,DB00583,L-Carnitine
,15848954,elimination rate constant,"The apparent efflux clearance of PTZ across the BBB was 137 microl/min/g brain, which was calculated from the elimination rate constant (5.35 x 10(-2) min(-1) and the distribution volume in the brain (2.56 ml/g brain).",In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),1/[min],5.35 x 10(-2),53254,DB00583,L-Carnitine
,15848954,distribution volume,"The apparent efflux clearance of PTZ across the BBB was 137 microl/min/g brain, which was calculated from the elimination rate constant (5.35 x 10(-2) min(-1) and the distribution volume in the brain (2.56 ml/g brain).",In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),[ml] / [brain·g],2.56,53255,DB00583,L-Carnitine
,26396135,Cmax,"The mean Cmax for the test and reference formulations were 1.74±0.43 μg/mL and 1.68±0.48 μg/mL, respectively.",Pharmacokinetic comparisons of two acetyl-L-carnitine formulations in healthy Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26396135/),[μg] / [ml],1.74,55066,DB00583,L-Carnitine
,26396135,Cmax,"The mean Cmax for the test and reference formulations were 1.74±0.43 μg/mL and 1.68±0.48 μg/mL, respectively.",Pharmacokinetic comparisons of two acetyl-L-carnitine formulations in healthy Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26396135/),[μg] / [ml],1.68,55067,DB00583,L-Carnitine
,26396135,AUClast,"The mean AUClast of ALC was 12.96±1.89 μg×h/mL and 12.49±2.44 μg×h/mL for the test and reference formulations, respectively.",Pharmacokinetic comparisons of two acetyl-L-carnitine formulations in healthy Korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26396135/),[h·μg] / [ml],12.96,55068,DB00583,L-Carnitine
,26396135,AUClast,"The mean AUClast of ALC was 12.96±1.89 μg×h/mL and 12.49±2.44 μg×h/mL for the test and reference formulations, respectively.",Pharmacokinetic comparisons of two acetyl-L-carnitine formulations in healthy Korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26396135/),[h·μg] / [ml],12.49,55069,DB00583,L-Carnitine
,10086992,Ki,"In isolated myocytes, THP inhibited free carnitine transport with a Ki of 1340 microM, which is considerably higher than the observed serum concentration of THP.","Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2, 2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10086992/),μM,1340,56089,DB00583,L-Carnitine
,10086992,Ki,"The estimated Ki of THP for inhibiting the reabsorption of free carnitine in kidneys was 52.2 microM, which is consistent with the serum THP concentration range.","Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2, 2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10086992/),μM,52.2,56090,DB00583,L-Carnitine
,9487550,absolute bioavailability (Bioav),"Nasal absorption characteristics of this formulation in the pH 4.0-6.3 range showed pH-dependency, with pH 4.0 showing the highest absolute bioavailability (Bioav) of 17.1%.",Nasal absorption kinetic behavior of azetirelin and its enhancement by acylcarnitines in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9487550/),%,17.1,61117,DB00583,L-Carnitine
,9487550,Bioav,This nasal Bioav was 21 times greater than that of oral administration (0.8%).,Nasal absorption kinetic behavior of azetirelin and its enhancement by acylcarnitines in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9487550/),%,0.8,61118,DB00583,L-Carnitine
,9487550,Bioavs,"Acylcarnitines with 12 or more carbon atoms in the acyl chain greatly enhanced nasal absorption of azetirelin: Bioavs with lauroylcarnitine chloride (LCC) and palmitoylcarnitine chloride were 96.9% and 72.9%, respectively.",Nasal absorption kinetic behavior of azetirelin and its enhancement by acylcarnitines in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9487550/),%,96.9,61119,DB00583,L-Carnitine
,9487550,Bioavs,"Acylcarnitines with 12 or more carbon atoms in the acyl chain greatly enhanced nasal absorption of azetirelin: Bioavs with lauroylcarnitine chloride (LCC) and palmitoylcarnitine chloride were 96.9% and 72.9%, respectively.",Nasal absorption kinetic behavior of azetirelin and its enhancement by acylcarnitines in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9487550/),%,72.9,61120,DB00583,L-Carnitine
,11069438,half-life,"At a dose of 1 g, PLC was found to have a mean (+/- s.d.) half-life of 1.09 +/- 0.15 h, a clearance of 11.6 +/- 0.24 l h-1 and a volume of distribution of 18.3 +/- 2.4 l.",Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069438/),h,1.09,65247,DB00583,L-Carnitine
,11069438,clearance,"At a dose of 1 g, PLC was found to have a mean (+/- s.d.) half-life of 1.09 +/- 0.15 h, a clearance of 11.6 +/- 0.24 l h-1 and a volume of distribution of 18.3 +/- 2.4 l.",Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069438/),[l] / [h],11.6,65248,DB00583,L-Carnitine
,11069438,volume of distribution,"At a dose of 1 g, PLC was found to have a mean (+/- s.d.) half-life of 1.09 +/- 0.15 h, a clearance of 11.6 +/- 0.24 l h-1 and a volume of distribution of 18.3 +/- 2.4 l.",Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069438/),l,18.3,65249,DB00583,L-Carnitine
less,11069438,renal excretory clearance to GFR ratios,"In placebo-treated subjects, endogenous PLC, LC and ALC underwent extensive renal tubular reabsorption, as indicated by renal excretory clearance to GFR ratios of less than 0.1.",Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069438/),,0.1,65250,DB00583,L-Carnitine
,11069438,renal-excretory clearance,"The renal-excretory clearance of PLC, which was 0.33 +/- 0.38 l h-1 under baseline condition, increased (P < 0. 001) from 1.98 +/- 0.59 l h-1 at a dose of 1 g to 5.55 +/- 1.50 l h-1 at a dose of 8 g (95% confidence interval for the difference was 2.18,4.97).",Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069438/),[l] / [h],0.33,65251,DB00583,L-Carnitine
,11069438,renal-excretory clearance,"The renal-excretory clearance of PLC, which was 0.33 +/- 0.38 l h-1 under baseline condition, increased (P < 0. 001) from 1.98 +/- 0.59 l h-1 at a dose of 1 g to 5.55 +/- 1.50 l h-1 at a dose of 8 g (95% confidence interval for the difference was 2.18,4.97).",Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069438/),[l] / [h],1.98,65252,DB00583,L-Carnitine
,11069438,renal-excretory clearance,"The renal-excretory clearance of PLC, which was 0.33 +/- 0.38 l h-1 under baseline condition, increased (P < 0. 001) from 1.98 +/- 0.59 l h-1 at a dose of 1 g to 5.55 +/- 1.50 l h-1 at a dose of 8 g (95% confidence interval for the difference was 2.18,4.97).",Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069438/),[l] / [h],5.55,65253,DB00583,L-Carnitine
,25227138,area under the curve,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[h·μg·∙] / [ml],"2,174.4",68858,DB00583,L-Carnitine
,25227138,biological half-life,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[h·μg·∙] / [ml],"3,128",68859,DB00583,L-Carnitine
,25227138,biological half-life,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),h,23.7,68860,DB00583,L-Carnitine
,25227138,biological half-life,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),h,8.87,68861,DB00583,L-Carnitine
,25227138,biological half-life,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[ml] / [h],13.9,68862,DB00583,L-Carnitine
,25227138,biological half-life,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[ml] / [h],151.1,68863,DB00583,L-Carnitine
,25227138,clearance,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[ml] / [h],13.9,68864,DB00583,L-Carnitine
,25227138,clearance,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[ml] / [h],151.1,68865,DB00583,L-Carnitine
,25227138,time of maximal concentration,"The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 μg/ml, and for the absorption rate constant 0.02 versus 2.40 h(-1), respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),h,0.58,68866,DB00583,L-Carnitine
,25227138,time of maximal concentration,"The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 μg/ml, and for the absorption rate constant 0.02 versus 2.40 h(-1), respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),h,1.53,68867,DB00583,L-Carnitine
,25227138,maximal concentration,"The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 μg/ml, and for the absorption rate constant 0.02 versus 2.40 h(-1), respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[μg] / [ml],62.4,68868,DB00583,L-Carnitine
,25227138,maximal concentration,"The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 μg/ml, and for the absorption rate constant 0.02 versus 2.40 h(-1), respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[μg] / [ml],221.4,68869,DB00583,L-Carnitine
,25227138,absorption rate constant,"The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 μg/ml, and for the absorption rate constant 0.02 versus 2.40 h(-1), respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),1/[h],0.02,68870,DB00583,L-Carnitine
,25227138,absorption rate constant,"The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 μg/ml, and for the absorption rate constant 0.02 versus 2.40 h(-1), respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),1/[h],2.40,68871,DB00583,L-Carnitine
,17879759,flow rate,The mobile phase consisted of 30% acetonitrile with 0.1 M ammonium acetate in water (pH 3.5) adjusted with acetic acid and delivered at a flow rate of 1.5 mL/ min.,Determination of highly soluble L-carnitine in biological samples by reverse phase high performance liquid chromatography with fluorescent derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879759/),[ml] / [min],1.5,73730,DB00583,L-Carnitine
,3220097,t1/2 beta of the elimination phase (beta),"Comparing the doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.11.h-1 for the 2 g and 6 g doses, respectively, showing dose-related elimination.",Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),h,6.5,75075,DB00583,L-Carnitine
,3220097,t1/2 beta of the elimination phase (beta),"Comparing the doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.11.h-1 for the 2 g and 6 g doses, respectively, showing dose-related elimination.",Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),h,3.9,75076,DB00583,L-Carnitine
,3220097,elimination constant,"Comparing the doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.11.h-1 for the 2 g and 6 g doses, respectively, showing dose-related elimination.",Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),1/[h],0.40,75077,DB00583,L-Carnitine
,3220097,elimination constant,"Comparing the doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.11.h-1 for the 2 g and 6 g doses, respectively, showing dose-related elimination.",Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),1/[h],0.50,75078,DB00583,L-Carnitine
,3220097,plasma carnitine,"Comparing the doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.11.h-1 for the 2 g and 6 g doses, respectively, showing dose-related elimination.",Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),1/[h],5.4,75079,DB00583,L-Carnitine
,3220097,plasma carnitine,"Comparing the doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.11.h-1 for the 2 g and 6 g doses, respectively, showing dose-related elimination.",Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),1/[h],6.11,75080,DB00583,L-Carnitine
,3220097,clearance,"Comparing the doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.11.h-1 for the 2 g and 6 g doses, respectively, showing dose-related elimination.",Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),1/[h],5.4,75081,DB00583,L-Carnitine
,3220097,clearance,"Comparing the doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.11.h-1 for the 2 g and 6 g doses, respectively, showing dose-related elimination.",Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),1/[h],6.11,75082,DB00583,L-Carnitine
,3220097,Urinary recoveries,"Urinary recoveries of the 2 g and 6 g doses were 70% and 82%, respectively, during the first 24 h.",Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),%,70,75083,DB00583,L-Carnitine
,3220097,Urinary recoveries,"Urinary recoveries of the 2 g and 6 g doses were 70% and 82%, respectively, during the first 24 h.",Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),%,82,75084,DB00583,L-Carnitine
,3220097,Urinary recovery,Urinary recovery was 8% and 4% for the 2 g and 6 g doses during the first 24 h.,Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),%,8,75085,DB00583,L-Carnitine
,3220097,Urinary recovery,Urinary recovery was 8% and 4% for the 2 g and 6 g doses during the first 24 h.,Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),%,4,75086,DB00583,L-Carnitine
,3220097,Oral bioavailability,Oral bioavailability was 16% for the 2 g dose and 5% for the 6 g dose.,Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),%,16,75087,DB00583,L-Carnitine
,3220097,Oral bioavailability,Oral bioavailability was 16% for the 2 g dose and 5% for the 6 g dose.,Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220097/),%,5,75088,DB00583,L-Carnitine
,3383994,C. V.,"The diurnal intraindividual variability of plasma carnitine was small (C. V. = 3.0, 3.9 and 3.9%, respectively), and the total 24 h excretion in urine was also small and relatively constant: 4.6, 21.5 and 13.0 mg/day in the controls vs 4.6, 20.2 and 6.0 mg/day during treatment in the three subjects to whom saline alone was administered according to a single-blind design.",Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383994/),%,3.0,76003,DB00583,L-Carnitine
,3383994,C. V.,"The diurnal intraindividual variability of plasma carnitine was small (C. V. = 3.0, 3.9 and 3.9%, respectively), and the total 24 h excretion in urine was also small and relatively constant: 4.6, 21.5 and 13.0 mg/day in the controls vs 4.6, 20.2 and 6.0 mg/day during treatment in the three subjects to whom saline alone was administered according to a single-blind design.",Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383994/),%,3.9,76004,DB00583,L-Carnitine
,3383994,total 24 h excretion,"The diurnal intraindividual variability of plasma carnitine was small (C. V. = 3.0, 3.9 and 3.9%, respectively), and the total 24 h excretion in urine was also small and relatively constant: 4.6, 21.5 and 13.0 mg/day in the controls vs 4.6, 20.2 and 6.0 mg/day during treatment in the three subjects to whom saline alone was administered according to a single-blind design.",Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383994/),[mg] / [d],4.6,76005,DB00583,L-Carnitine
,3383994,total 24 h excretion,"The diurnal intraindividual variability of plasma carnitine was small (C. V. = 3.0, 3.9 and 3.9%, respectively), and the total 24 h excretion in urine was also small and relatively constant: 4.6, 21.5 and 13.0 mg/day in the controls vs 4.6, 20.2 and 6.0 mg/day during treatment in the three subjects to whom saline alone was administered according to a single-blind design.",Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383994/),[mg] / [d],21.5,76006,DB00583,L-Carnitine
,3383994,total 24 h excretion,"The diurnal intraindividual variability of plasma carnitine was small (C. V. = 3.0, 3.9 and 3.9%, respectively), and the total 24 h excretion in urine was also small and relatively constant: 4.6, 21.5 and 13.0 mg/day in the controls vs 4.6, 20.2 and 6.0 mg/day during treatment in the three subjects to whom saline alone was administered according to a single-blind design.",Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383994/),[mg] / [d],13.0,76007,DB00583,L-Carnitine
,3383994,total 24 h excretion,"The diurnal intraindividual variability of plasma carnitine was small (C. V. = 3.0, 3.9 and 3.9%, respectively), and the total 24 h excretion in urine was also small and relatively constant: 4.6, 21.5 and 13.0 mg/day in the controls vs 4.6, 20.2 and 6.0 mg/day during treatment in the three subjects to whom saline alone was administered according to a single-blind design.",Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383994/),[mg] / [d],20.2,76008,DB00583,L-Carnitine
,3383994,total 24 h excretion,"The diurnal intraindividual variability of plasma carnitine was small (C. V. = 3.0, 3.9 and 3.9%, respectively), and the total 24 h excretion in urine was also small and relatively constant: 4.6, 21.5 and 13.0 mg/day in the controls vs 4.6, 20.2 and 6.0 mg/day during treatment in the three subjects to whom saline alone was administered according to a single-blind design.",Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383994/),[mg] / [d],6.0,76009,DB00583,L-Carnitine
,3383994,Vc,"Plasma carnitine fitted well to a three-compartment open model, with Vc of 0.11-0.20 l/kg and a t1/2 gamma of 10-23 h.",Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383994/),[l] / [kg],0.11-0.20,76010,DB00583,L-Carnitine
,3383994,t1/2 gamma,"Plasma carnitine fitted well to a three-compartment open model, with Vc of 0.11-0.20 l/kg and a t1/2 gamma of 10-23 h.",Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383994/),h,10-23,76011,DB00583,L-Carnitine
,3383994,urine recovery,The urine recovery in 24 h was 77.2-95.4%.,Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383994/),%,77.2-95.4,76012,DB00583,L-Carnitine
,24337254,Bioavailability,"Bioavailability of carnitine and acylcarnitines, determined as the urinary excretion of total carnitine, was in the range of 19 %.","Effect of carnitine, acetyl-, and propionylcarnitine supplementation on the body carnitine pool, skeletal muscle composition, and physical performance in mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24337254/),%,19,91511,DB00583,L-Carnitine
,8517691,a,"In three elderly patients with declining renal function (creatinine clearance rate, 31 to 50 ml/min), the acylcarnitine/free carnitine ratio increased from 0.1 to 0.4 up to 0.7 to 1.5 at day 5 during the 7-day treatment, showed a tendency to decrease, and then returned to the pretreatment ratio 4 days after discontinuation of the drug.","Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8517691/),,0.1,102080,DB00583,L-Carnitine
,8517691,a,"In three elderly patients with declining renal function (creatinine clearance rate, 31 to 50 ml/min), the acylcarnitine/free carnitine ratio increased from 0.1 to 0.4 up to 0.7 to 1.5 at day 5 during the 7-day treatment, showed a tendency to decrease, and then returned to the pretreatment ratio 4 days after discontinuation of the drug.","Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8517691/),,0.4,102081,DB00583,L-Carnitine
,8517691,a,"In three elderly patients with declining renal function (creatinine clearance rate, 31 to 50 ml/min), the acylcarnitine/free carnitine ratio increased from 0.1 to 0.4 up to 0.7 to 1.5 at day 5 during the 7-day treatment, showed a tendency to decrease, and then returned to the pretreatment ratio 4 days after discontinuation of the drug.","Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8517691/),,0,102082,DB00583,L-Carnitine
,8517691,a,"In three elderly patients with declining renal function (creatinine clearance rate, 31 to 50 ml/min), the acylcarnitine/free carnitine ratio increased from 0.1 to 0.4 up to 0.7 to 1.5 at day 5 during the 7-day treatment, showed a tendency to decrease, and then returned to the pretreatment ratio 4 days after discontinuation of the drug.","Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8517691/),,1,102083,DB00583,L-Carnitine
,8986559,reached steady state levels,"During the treatment period, plasma total carnitine decreased slowly down to 25.5 microM (group A) and 38.8 microM (group B) and plasma free carnitine reached steady state levels at 17.7 microM (group A) and 29.2 microM (group B) on day 5.",[Influence of multiple-dose administration of cefetamet pivoxil on blood and urinary concentrations of carnitine and effects of simultaneous administration of carnitine with cefetamet pivoxil]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8986559/),μM,17.7,102947,DB00583,L-Carnitine
,8986559,reached steady state levels,"During the treatment period, plasma total carnitine decreased slowly down to 25.5 microM (group A) and 38.8 microM (group B) and plasma free carnitine reached steady state levels at 17.7 microM (group A) and 29.2 microM (group B) on day 5.",[Influence of multiple-dose administration of cefetamet pivoxil on blood and urinary concentrations of carnitine and effects of simultaneous administration of carnitine with cefetamet pivoxil]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8986559/),μM,29.2,102948,DB00583,L-Carnitine
,8986559,bioavailability,"This was considered attributable to the fact that the bioavailability of carnitine is as low as 16% when administered orally, which is considerably less compared to the 55% bioavailability of cefetamet pivoxil.",[Influence of multiple-dose administration of cefetamet pivoxil on blood and urinary concentrations of carnitine and effects of simultaneous administration of carnitine with cefetamet pivoxil]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8986559/),%,16,102949,DB00583,L-Carnitine
,8986559,bioavailability,"This was considered attributable to the fact that the bioavailability of carnitine is as low as 16% when administered orally, which is considerably less compared to the 55% bioavailability of cefetamet pivoxil.",[Influence of multiple-dose administration of cefetamet pivoxil on blood and urinary concentrations of carnitine and effects of simultaneous administration of carnitine with cefetamet pivoxil]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8986559/),%,55,102950,DB00583,L-Carnitine
,3751959,total plasma-carnitine concentration,"As early as the 8th wk of pregnancy, the mean (+/- SD) value of total plasma-carnitine concentration in 19 women was significantly decreased from 39.0 +/- 6.3 to 32.8 +/- 4.6 mumol/l and the values continued to fall to 17.3 mumol/l by the 36th wk.",Plasma carnitine and renal-carnitine clearance during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3751959/),mum,39.0,104514,DB00583,L-Carnitine
,3751959,total plasma-carnitine concentration,"As early as the 8th wk of pregnancy, the mean (+/- SD) value of total plasma-carnitine concentration in 19 women was significantly decreased from 39.0 +/- 6.3 to 32.8 +/- 4.6 mumol/l and the values continued to fall to 17.3 mumol/l by the 36th wk.",Plasma carnitine and renal-carnitine clearance during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3751959/),mum,32.8,104515,DB00583,L-Carnitine
,3751959,total plasma-carnitine concentration,"As early as the 8th wk of pregnancy, the mean (+/- SD) value of total plasma-carnitine concentration in 19 women was significantly decreased from 39.0 +/- 6.3 to 32.8 +/- 4.6 mumol/l and the values continued to fall to 17.3 mumol/l by the 36th wk.",Plasma carnitine and renal-carnitine clearance during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3751959/),mum,17.3,104516,DB00583,L-Carnitine
,3751959,renal clearance,"In 12 other women examined during late pregnancy, the renal clearance of acylcarnitine was significantly higher than in nonpregnant women, 53.9 +/- 29.4 versus 13.3 +/- 3.0 ml/min, in contrast to free carnitine, 3.5 +/- 2.8 versus 2.8 +/- 1.9 ml/min.",Plasma carnitine and renal-carnitine clearance during pregnancy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3751959/),[ml] / [min],53.9,104517,DB00583,L-Carnitine
,3751959,renal clearance,"In 12 other women examined during late pregnancy, the renal clearance of acylcarnitine was significantly higher than in nonpregnant women, 53.9 +/- 29.4 versus 13.3 +/- 3.0 ml/min, in contrast to free carnitine, 3.5 +/- 2.8 versus 2.8 +/- 1.9 ml/min.",Plasma carnitine and renal-carnitine clearance during pregnancy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3751959/),[ml] / [min],13.3,104518,DB00583,L-Carnitine
,3751959,renal clearance,"In 12 other women examined during late pregnancy, the renal clearance of acylcarnitine was significantly higher than in nonpregnant women, 53.9 +/- 29.4 versus 13.3 +/- 3.0 ml/min, in contrast to free carnitine, 3.5 +/- 2.8 versus 2.8 +/- 1.9 ml/min.",Plasma carnitine and renal-carnitine clearance during pregnancy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3751959/),[ml] / [min],3.5,104519,DB00583,L-Carnitine
,3751959,renal clearance,"In 12 other women examined during late pregnancy, the renal clearance of acylcarnitine was significantly higher than in nonpregnant women, 53.9 +/- 29.4 versus 13.3 +/- 3.0 ml/min, in contrast to free carnitine, 3.5 +/- 2.8 versus 2.8 +/- 1.9 ml/min.",Plasma carnitine and renal-carnitine clearance during pregnancy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3751959/),[ml] / [min],2.8,104520,DB00583,L-Carnitine
,8272416,bioavailability (F),"While the bioavailability (F) of tablets containing 12 mg CEF without PCC ranged from 0.6 to 3.9%, the addition of 24 mg PCC resulted in an enhanced CEF bioavailability in the rat colon (mean +/- SD: F = 57 +/- 19%) and rat jejunum (F = 71 +/- 16%) but not in the rat stomach.",Enhanced bioavailability of cefoxitin using palmitoylcarnitine. Use of directly compressed tablet formulations in the rat and dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272416/),%,0.6 to 3.9,105723,DB00583,L-Carnitine
,8272416,F,"While the bioavailability (F) of tablets containing 12 mg CEF without PCC ranged from 0.6 to 3.9%, the addition of 24 mg PCC resulted in an enhanced CEF bioavailability in the rat colon (mean +/- SD: F = 57 +/- 19%) and rat jejunum (F = 71 +/- 16%) but not in the rat stomach.",Enhanced bioavailability of cefoxitin using palmitoylcarnitine. Use of directly compressed tablet formulations in the rat and dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272416/),%,57,105724,DB00583,L-Carnitine
,8272416,F,"While the bioavailability (F) of tablets containing 12 mg CEF without PCC ranged from 0.6 to 3.9%, the addition of 24 mg PCC resulted in an enhanced CEF bioavailability in the rat colon (mean +/- SD: F = 57 +/- 19%) and rat jejunum (F = 71 +/- 16%) but not in the rat stomach.",Enhanced bioavailability of cefoxitin using palmitoylcarnitine. Use of directly compressed tablet formulations in the rat and dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272416/),%,71,105725,DB00583,L-Carnitine
,8272416,bioavailabilities,"Following oral administration to dogs, tablets of 200 mg CEF without or with 600 mg PCC resulted in the same low bioavailabilities (7.0 +/- 10.3 and 7.0 +/- 3.6%, respectively).",Enhanced bioavailability of cefoxitin using palmitoylcarnitine. Use of directly compressed tablet formulations in the rat and dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272416/),%,7.0,105726,DB00583,L-Carnitine
,8272416,bioavailabilities,"Following oral administration to dogs, tablets of 200 mg CEF without or with 600 mg PCC resulted in the same low bioavailabilities (7.0 +/- 10.3 and 7.0 +/- 3.6%, respectively).",Enhanced bioavailability of cefoxitin using palmitoylcarnitine. Use of directly compressed tablet formulations in the rat and dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272416/),%,7.0,105727,DB00583,L-Carnitine
,8272416,bioavailability,"However, when these tablets were enteric coated, PCC improved CEF bioavailability from 2.44 +/- 1.84 to 29.0 +/- 13.4%.",Enhanced bioavailability of cefoxitin using palmitoylcarnitine. Use of directly compressed tablet formulations in the rat and dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272416/),%,2.44,105728,DB00583,L-Carnitine
,8272416,bioavailability,"However, when these tablets were enteric coated, PCC improved CEF bioavailability from 2.44 +/- 1.84 to 29.0 +/- 13.4%.",Enhanced bioavailability of cefoxitin using palmitoylcarnitine. Use of directly compressed tablet formulations in the rat and dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272416/),%,29.0,105729,DB00583,L-Carnitine
,7658357,volumes of distribution at steady state (Vdss) of the central compartment,"For free L-carnitine, mean volumes of distribution at steady state (Vdss) of the central compartment were similar using either approach (9.86 versus 11.2 L).",Comparison of L-carnitine pharmacokinetics with and without baseline correction following administration of single 20-mg/kg intravenous dose. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658357/),l,9.86,110292,DB00583,L-Carnitine
,7658357,volumes of distribution at steady state (Vdss) of the central compartment,"For free L-carnitine, mean volumes of distribution at steady state (Vdss) of the central compartment were similar using either approach (9.86 versus 11.2 L).",Comparison of L-carnitine pharmacokinetics with and without baseline correction following administration of single 20-mg/kg intravenous dose. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658357/),l,11.2,110293,DB00583,L-Carnitine
,7658357,Vdss,"However, Vdss (54.0 versus 29.0 L) and apparent elimination half-life (17.4 versus 5.0 h) were significantly different between the two data bases.",Comparison of L-carnitine pharmacokinetics with and without baseline correction following administration of single 20-mg/kg intravenous dose. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658357/),l,54.0,110294,DB00583,L-Carnitine
,7658357,Vdss,"However, Vdss (54.0 versus 29.0 L) and apparent elimination half-life (17.4 versus 5.0 h) were significantly different between the two data bases.",Comparison of L-carnitine pharmacokinetics with and without baseline correction following administration of single 20-mg/kg intravenous dose. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658357/),l,29.0,110295,DB00583,L-Carnitine
,7658357,apparent elimination half-life,"However, Vdss (54.0 versus 29.0 L) and apparent elimination half-life (17.4 versus 5.0 h) were significantly different between the two data bases.",Comparison of L-carnitine pharmacokinetics with and without baseline correction following administration of single 20-mg/kg intravenous dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658357/),h,17.4,110296,DB00583,L-Carnitine
,7658357,apparent elimination half-life,"However, Vdss (54.0 versus 29.0 L) and apparent elimination half-life (17.4 versus 5.0 h) were significantly different between the two data bases.",Comparison of L-carnitine pharmacokinetics with and without baseline correction following administration of single 20-mg/kg intravenous dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658357/),h,5.0,110297,DB00583,L-Carnitine
,1503437,Recoveries,"Recoveries in urine at the doses of S-1108 given (100 and 200 mg) were 33 to 41% for S-1006, 93% for total pivalic acid, and 89 to 94% for pivaloylcarnitine in 24 h, and maximum concentrations in plasma were 2 micrograms of S-1006 per ml, 1 micrograms of total pivalic acid per ml, and 2 micrograms of pivaloylcarnitine per ml after a 200-mg oral administration of S-1108.","Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503437/),%,33 to 41,115953,DB00583,L-Carnitine
,1503437,Recoveries,"Recoveries in urine at the doses of S-1108 given (100 and 200 mg) were 33 to 41% for S-1006, 93% for total pivalic acid, and 89 to 94% for pivaloylcarnitine in 24 h, and maximum concentrations in plasma were 2 micrograms of S-1006 per ml, 1 micrograms of total pivalic acid per ml, and 2 micrograms of pivaloylcarnitine per ml after a 200-mg oral administration of S-1108.","Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503437/),%,93,115954,DB00583,L-Carnitine
,1503437,Recoveries,"Recoveries in urine at the doses of S-1108 given (100 and 200 mg) were 33 to 41% for S-1006, 93% for total pivalic acid, and 89 to 94% for pivaloylcarnitine in 24 h, and maximum concentrations in plasma were 2 micrograms of S-1006 per ml, 1 micrograms of total pivalic acid per ml, and 2 micrograms of pivaloylcarnitine per ml after a 200-mg oral administration of S-1108.","Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503437/),%,89 to 94,115955,DB00583,L-Carnitine
,1503437,maximum concentrations,"Recoveries in urine at the doses of S-1108 given (100 and 200 mg) were 33 to 41% for S-1006, 93% for total pivalic acid, and 89 to 94% for pivaloylcarnitine in 24 h, and maximum concentrations in plasma were 2 micrograms of S-1006 per ml, 1 micrograms of total pivalic acid per ml, and 2 micrograms of pivaloylcarnitine per ml after a 200-mg oral administration of S-1108.","Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503437/),μg,2,115956,DB00583,L-Carnitine
,1503437,maximum concentrations,"Recoveries in urine at the doses of S-1108 given (100 and 200 mg) were 33 to 41% for S-1006, 93% for total pivalic acid, and 89 to 94% for pivaloylcarnitine in 24 h, and maximum concentrations in plasma were 2 micrograms of S-1006 per ml, 1 micrograms of total pivalic acid per ml, and 2 micrograms of pivaloylcarnitine per ml after a 200-mg oral administration of S-1108.","Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503437/),μg,1,115957,DB00583,L-Carnitine
,1475789,half-lives,"After the treatment with carnitine, serum carnitine concentration was increased, and prolonged half-lives of VPA were corrected near to the normal range (from 12.2 +/- 4.2 hr to 9.7 +/- 2.2 hr; p < 0.05).",The effect of carnitine on the metabolism of valproic acid in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1475789/),h,12.2,116820,DB00583,L-Carnitine
,1475789,half-lives,"After the treatment with carnitine, serum carnitine concentration was increased, and prolonged half-lives of VPA were corrected near to the normal range (from 12.2 +/- 4.2 hr to 9.7 +/- 2.2 hr; p < 0.05).",The effect of carnitine on the metabolism of valproic acid in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1475789/),h,9.7,116821,DB00583,L-Carnitine
,7614519,oral systemic bioavailability,"The oral systemic bioavailability of carnitine in normal subjects is 5% to 16%, with peak plasma carnitine concentrations reached 2 to 6 hours after dosing.",Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614519/),%,5,119463,DB00583,L-Carnitine
,7614519,oral systemic bioavailability,"The oral systemic bioavailability of carnitine in normal subjects is 5% to 16%, with peak plasma carnitine concentrations reached 2 to 6 hours after dosing.",Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614519/),%,16,119464,DB00583,L-Carnitine
,23907530,Km,"The specific uptake of thiamine was observed in MATE1-, MATE2-K- or OCT2-expressing HEK293 cells with Km of 3.5 ± 1.0, 3.9 ± 0.8 and 59.9 ± 6.7 μM, respectively.",Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23907530/),μM,3.5,119937,DB00583,L-Carnitine
,23907530,Km,"The specific uptake of thiamine was observed in MATE1-, MATE2-K- or OCT2-expressing HEK293 cells with Km of 3.5 ± 1.0, 3.9 ± 0.8 and 59.9 ± 6.7 μM, respectively.",Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23907530/),μM,3.9,119938,DB00583,L-Carnitine
,23907530,Km,"The specific uptake of thiamine was observed in MATE1-, MATE2-K- or OCT2-expressing HEK293 cells with Km of 3.5 ± 1.0, 3.9 ± 0.8 and 59.9 ± 6.7 μM, respectively.",Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23907530/),μM,59.9,119939,DB00583,L-Carnitine
,1541322,t1/2,"Following the i.v. bolus injections, the plasma concentrations showed a biphasic curve, with average t1/2 of 0.073 h and 1.73 h, respectively.",Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1541322/),h,0.073,120650,DB00583,L-Carnitine
,1541322,t1/2,"Following the i.v. bolus injections, the plasma concentrations showed a biphasic curve, with average t1/2 of 0.073 h and 1.73 h, respectively.",Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1541322/),h,1.73,120651,DB00583,L-Carnitine
,2081201,elimination half-life,"The elimination half-life was very short, 2.43 +/- 0.35 h, despite the reduced plasma clearance of 41.2 +/- 5.7 ml min-1, compared with healthy adults.",Kinetics of intravenously administered carnitine in haemodialysed children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2081201/),h,2.43,128670,DB00583,L-Carnitine
,2081201,plasma clearance,"The elimination half-life was very short, 2.43 +/- 0.35 h, despite the reduced plasma clearance of 41.2 +/- 5.7 ml min-1, compared with healthy adults.",Kinetics of intravenously administered carnitine in haemodialysed children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2081201/),[ml] / [min],41.2,128671,DB00583,L-Carnitine
,2081201,apparent volume of distribution,"The apparent volume of distribution, 0.27 +/- 0.07 1 kg-1 body wt, corresponds well to the size of the extracellular space.",Kinetics of intravenously administered carnitine in haemodialysed children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2081201/),[1] / [kg],0.27,128672,DB00583,L-Carnitine
,19178874,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) and area under the curve (AUC 0-infinity) of L-carnitine was 84.7+/-25.2 micromol x L(-1) x h and 2676.4+/-708.3 micromol x L(-1) x h, respectively.","Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19178874/),[h·μM] / [l],84.7,139317,DB00583,L-Carnitine
,19178874,area under the curve (AUC 0-infinity),"The maximum plasma concentration (Cmax) and area under the curve (AUC 0-infinity) of L-carnitine was 84.7+/-25.2 micromol x L(-1) x h and 2676.4+/-708.3 micromol x L(-1) x h, respectively.","Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19178874/),[h·μM] / [l],2676.4,139318,DB00583,L-Carnitine
,19178874,elimination half-life,"The elimination half-life of L-carnitine and the time required to reach the Cmax (Tmax) was 60.3+/-15.0 and 3.4+/-0.46 h, respectively.","Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19178874/),h,60.3,139319,DB00583,L-Carnitine
,19178874,time required to reach the Cmax (Tmax),"The elimination half-life of L-carnitine and the time required to reach the Cmax (Tmax) was 60.3+/-15.0 and 3.4+/-0.46 h, respectively.","Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19178874/),h,3.4,139320,DB00583,L-Carnitine
,19178874,Cmax,"The Cmax of ALC (12.9+/-5.5 micromol x L(-1)) and PLC (5.08+/-3.08 micromol x L(-1)) was lower than L-carnitine (P < 0.01), so as the AUC 0-infinity (166.2+/-77.4 and 155.6+/-264.2 micromol x L(-1) x h, respectively, P < 0.01).","Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19178874/),[μM] / [l],12.9,139321,DB00583,L-Carnitine
,19178874,Cmax,"The Cmax of ALC (12.9+/-5.5 micromol x L(-1)) and PLC (5.08+/-3.08 micromol x L(-1)) was lower than L-carnitine (P < 0.01), so as the AUC 0-infinity (166.2+/-77.4 and 155.6+/-264.2 micromol x L(-1) x h, respectively, P < 0.01).","Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19178874/),[μM] / [l],5.08,139322,DB00583,L-Carnitine
,19178874,AUC 0-infinity,"The Cmax of ALC (12.9+/-5.5 micromol x L(-1)) and PLC (5.08+/-3.08 micromol x L(-1)) was lower than L-carnitine (P < 0.01), so as the AUC 0-infinity (166.2+/-77.4 and 155.6+/-264.2 micromol x L(-1) x h, respectively, P < 0.01).","Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19178874/),[h·μM] / [l],166.2,139323,DB00583,L-Carnitine
,19178874,AUC 0-infinity,"The Cmax of ALC (12.9+/-5.5 micromol x L(-1)) and PLC (5.08+/-3.08 micromol x L(-1)) was lower than L-carnitine (P < 0.01), so as the AUC 0-infinity (166.2+/-77.4 and 155.6+/-264.2 micromol x L(-1) x h, respectively, P < 0.01).","Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19178874/),[h·μM] / [l],155.6,139324,DB00583,L-Carnitine
,19178874,half-life,The half-life of ALC (35.9+/-28.9h) and PLC (25.7+/-30.3 h) was also shorter than L-carnitine (P < 0.01).,"Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19178874/),h,35.9,139325,DB00583,L-Carnitine
,19178874,half-life,The half-life of ALC (35.9+/-28.9h) and PLC (25.7+/-30.3 h) was also shorter than L-carnitine (P < 0.01).,"Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19178874/),h,25.7,139326,DB00583,L-Carnitine
,19178874,accumulated urinary excretion,"The 24h accumulated urinary excretion of L-carnitine, ALC and PLC were 613.5+/-161.7, 368.3+/-134.8 and 61.3+/-37.8 micromol, respectively.","Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19178874/),μM,613.5,139327,DB00583,L-Carnitine
,19178874,accumulated urinary excretion,"The 24h accumulated urinary excretion of L-carnitine, ALC and PLC were 613.5+/-161.7, 368.3+/-134.8 and 61.3+/-37.8 micromol, respectively.","Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19178874/),μM,368.3,139328,DB00583,L-Carnitine
,19178874,accumulated urinary excretion,"The 24h accumulated urinary excretion of L-carnitine, ALC and PLC were 613.5+/-161.7, 368.3+/-134.8 and 61.3+/-37.8 micromol, respectively.","Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19178874/),μM,61.3,139329,DB00583,L-Carnitine
,2395807,relative bioavailability,"A lysophospholipid, lysophosphatidylcholine, gave the highest peak concentration, with an increase in peak height of 450% and a relative bioavailability of 25.8%.",Nasal absorption enhancers for biosynthetic human growth hormone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395807/),%,25.8,144697,DB00583,L-Carnitine
,2395807,relative bioavailability,"However, the greatest increase in AUC (291%) was achieved with the aminopeptidase inhibitor, amastatin, which gave a relative bioavailability of 28.9%.",Nasal absorption enhancers for biosynthetic human growth hormone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395807/),%,28.9,144698,DB00583,L-Carnitine
,2395807,relative bioavailabilities,"A mucolytic agent, N-acetyl-L-cysteine, and a transmembrane fatty acid transporter, palmitoyl-DL-carnitine, were also found to promote the nasal absorption of hGH in this model, with relative bioavailabilities of 12.2 and 22.1%, respectively.",Nasal absorption enhancers for biosynthetic human growth hormone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395807/),%,12.2,144699,DB00583,L-Carnitine
,2395807,relative bioavailabilities,"A mucolytic agent, N-acetyl-L-cysteine, and a transmembrane fatty acid transporter, palmitoyl-DL-carnitine, were also found to promote the nasal absorption of hGH in this model, with relative bioavailabilities of 12.2 and 22.1%, respectively.",Nasal absorption enhancers for biosynthetic human growth hormone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395807/),%,22.1,144700,DB00583,L-Carnitine
,2007906,Total radioactive metabolites excreted,Total radioactive metabolites excreted ranged from 13 to 34% (low carnitine diet) and 27 to 46% (high carnitine diet) of the ingested tracer.,Metabolic fate of dietary carnitine in human adults: identification and quantification of urinary and fecal metabolites. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007906/),%,13 to 34,151024,DB00583,L-Carnitine
,2007906,Total radioactive metabolites excreted,Total radioactive metabolites excreted ranged from 13 to 34% (low carnitine diet) and 27 to 46% (high carnitine diet) of the ingested tracer.,Metabolic fate of dietary carnitine in human adults: identification and quantification of urinary and fecal metabolites. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007906/),%,27 to 46,151025,DB00583,L-Carnitine
,2007906,Urinary excretion,Urinary excretion of total carnitine was 42 to 95% (high carnitine diet) and 190 to 364% (low carnitine diet) of intake.,Metabolic fate of dietary carnitine in human adults: identification and quantification of urinary and fecal metabolites. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007906/),%,42 to 95,151026,DB00583,L-Carnitine
,2007906,Urinary excretion,Urinary excretion of total carnitine was 42 to 95% (high carnitine diet) and 190 to 364% (low carnitine diet) of intake.,Metabolic fate of dietary carnitine in human adults: identification and quantification of urinary and fecal metabolites. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007906/),%,190 to 364,151027,DB00583,L-Carnitine
,2007906,bioavailable,These results indicate that oral carnitine is 54 to 87% bioavailable from normal Western diets; the percentage of intake absorbed is related to the quantity ingested.,Metabolic fate of dietary carnitine in human adults: identification and quantification of urinary and fecal metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007906/),%,54 to 87,151028,DB00583,L-Carnitine
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,121,151323,DB00583,L-Carnitine
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,859,151324,DB00583,L-Carnitine
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,1888,151325,DB00583,L-Carnitine
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,1880,151326,DB00583,L-Carnitine
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,117,151327,DB00583,L-Carnitine
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,1207,151328,DB00583,L-Carnitine
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,1498,151329,DB00583,L-Carnitine
,1503438,half-life,"The half-life and area under the concentration-time curve of S-1006 was reduced from 1.11 +/- 0.17 h at the first dose to 0.87 +/- 0.18 h at the last dose and from 7.30 +/- 1.10 to 5.20 +/- 0.85 micrograms.h/ml, respectively.",Phase I clinical studies of S-1108: safety and pharmacokinetics in a multiple-administration study with special emphasis on the influence on carnitine body stores. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503438/),h,1.11,151894,DB00583,L-Carnitine
,1503438,half-life,"The half-life and area under the concentration-time curve of S-1006 was reduced from 1.11 +/- 0.17 h at the first dose to 0.87 +/- 0.18 h at the last dose and from 7.30 +/- 1.10 to 5.20 +/- 0.85 micrograms.h/ml, respectively.",Phase I clinical studies of S-1108: safety and pharmacokinetics in a multiple-administration study with special emphasis on the influence on carnitine body stores. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503438/),h,0.87,151895,DB00583,L-Carnitine
,1503438,area under the concentration-time curve,"The half-life and area under the concentration-time curve of S-1006 was reduced from 1.11 +/- 0.17 h at the first dose to 0.87 +/- 0.18 h at the last dose and from 7.30 +/- 1.10 to 5.20 +/- 0.85 micrograms.h/ml, respectively.",Phase I clinical studies of S-1108: safety and pharmacokinetics in a multiple-administration study with special emphasis on the influence on carnitine body stores. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503438/),[h·μg] / [ml],7.30,151896,DB00583,L-Carnitine
,1503438,area under the concentration-time curve,"The half-life and area under the concentration-time curve of S-1006 was reduced from 1.11 +/- 0.17 h at the first dose to 0.87 +/- 0.18 h at the last dose and from 7.30 +/- 1.10 to 5.20 +/- 0.85 micrograms.h/ml, respectively.",Phase I clinical studies of S-1108: safety and pharmacokinetics in a multiple-administration study with special emphasis on the influence on carnitine body stores. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503438/),[h·μg] / [ml],5.20,151897,DB00583,L-Carnitine
,1503438,total urinary recovery,"The total urinary recovery of pivalic acid as pivaloylcarnitine was 98.7 +/- 3.6%, resulting in an increase of daily carnitine urinary excretion two- to threefold the predose value.",Phase I clinical studies of S-1108: safety and pharmacokinetics in a multiple-administration study with special emphasis on the influence on carnitine body stores. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503438/),%,98.7,151898,DB00583,L-Carnitine
,19220985,K(m),"The CER transport by OCTN2 exhibited saturation with K(m) of approximately 3 mM, which is similar to the renal CER concentration exhibiting saturation in renal clearance in vivo.",Carnitine/organic cation transporter OCTN2 (Slc22a5) is responsible for renal secretion of cephaloridine in mice. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19220985/),mM,3,152132,DB00583,L-Carnitine
greater,19271547,Absorption rate,"Absorption rate of the supplemented carnitine in the small intestine, assessed by the use of titanium dioxide as an indigestible indicator, was greater than 95% for the lower doses (25, 50, 100 mg/kg) and greater than 90% for the higher doses (200, 500, 1000 mg/kg).",Supplementation of L-carnitine in pigs: absorption of carnitine and effect on plasma and tissue carnitine concentrations. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19271547/),%,95,152623,DB00583,L-Carnitine
greater,19271547,Absorption rate,"Absorption rate of the supplemented carnitine in the small intestine, assessed by the use of titanium dioxide as an indigestible indicator, was greater than 95% for the lower doses (25, 50, 100 mg/kg) and greater than 90% for the higher doses (200, 500, 1000 mg/kg).",Supplementation of L-carnitine in pigs: absorption of carnitine and effect on plasma and tissue carnitine concentrations. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19271547/),%,90,152624,DB00583,L-Carnitine
,8240461,half-life of distribution t1/2 alpha,"The half-life of distribution t1/2 alpha to 0.68 h (+154%), the terminal half-life t1/2 beta to 7.94 h (+140%), whereas the total clearance decreased by 400% as compared with the standard carnitine administration.",Pharmacokinetics and organ distribution of liposome-encapsulated L-carnitine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240461/),h,0.68,152945,DB00583,L-Carnitine
,8240461,terminal half-life t1/2 beta,"The half-life of distribution t1/2 alpha to 0.68 h (+154%), the terminal half-life t1/2 beta to 7.94 h (+140%), whereas the total clearance decreased by 400% as compared with the standard carnitine administration.",Pharmacokinetics and organ distribution of liposome-encapsulated L-carnitine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240461/),h,7.94,152946,DB00583,L-Carnitine
,8240461,t1/2,"The novel dosage form is stable in vitro (t1/2 4 degree C = 187 days) as well as in vivo and, thus, may be successfully used in the therapy of carnitine deficiency, for instance in patients with renal failure or liver disease.",Pharmacokinetics and organ distribution of liposome-encapsulated L-carnitine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240461/),d,187,152947,DB00583,L-Carnitine
,9703262,fractions absorbed,"The fractions absorbed were estimated to be 96.7 and 33.0% for the low and high doses, respectively, as these were the fractions that disappeared from the gastrointestinal tract.",Fractional absorption of L-carnitine after oral administration in rats: evaluation of absorption site and dose dependency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9703262/),%,96.7,154725,DB00583,L-Carnitine
,9703262,fractions absorbed,"The fractions absorbed were estimated to be 96.7 and 33.0% for the low and high doses, respectively, as these were the fractions that disappeared from the gastrointestinal tract.",Fractional absorption of L-carnitine after oral administration in rats: evaluation of absorption site and dose dependency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9703262/),%,33.0,154726,DB00583,L-Carnitine
,9703262,bioavailability,"These values were comparable with 100 and 42%, respectively, of bioavailability values by the pharmacokinetic analysis of plasma concentration data in our preceding study [Matsuda et al., Biopharmaceutics & Drug Disposition, in press].",Fractional absorption of L-carnitine after oral administration in rats: evaluation of absorption site and dose dependency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9703262/),%,100,154727,DB00583,L-Carnitine
,9703262,bioavailability,"These values were comparable with 100 and 42%, respectively, of bioavailability values by the pharmacokinetic analysis of plasma concentration data in our preceding study [Matsuda et al., Biopharmaceutics & Drug Disposition, in press].",Fractional absorption of L-carnitine after oral administration in rats: evaluation of absorption site and dose dependency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9703262/),%,42,154728,DB00583,L-Carnitine
,15283472,Quantitation,Quantitation limit was 0.1 microg/mL.,HPLC determination and pharmacokinetics of endogenous acetyl-L-carnitine (ALC) in human volunteers orally administered a single dose of ALC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283472/),μg,0.1,155564,DB00583,L-Carnitine
,15283472,"half-life (t(1/2,beta))","After oral administration of a 500 mg ALC tablet to 8 healthy volunteers, the principle pharmacokinetic parameters were 4.2 h of the half-life (t(1/2,beta)), the area under the curve (AUC(0-8)) of 9.88 microg.h/mL, and 3.1 h of the time (Tmax) to reach Cmax.",HPLC determination and pharmacokinetics of endogenous acetyl-L-carnitine (ALC) in human volunteers orally administered a single dose of ALC. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283472/),h,4.2,155565,DB00583,L-Carnitine
,15283472,area under the curve (AUC(0-8)),"After oral administration of a 500 mg ALC tablet to 8 healthy volunteers, the principle pharmacokinetic parameters were 4.2 h of the half-life (t(1/2,beta)), the area under the curve (AUC(0-8)) of 9.88 microg.h/mL, and 3.1 h of the time (Tmax) to reach Cmax.",HPLC determination and pharmacokinetics of endogenous acetyl-L-carnitine (ALC) in human volunteers orally administered a single dose of ALC. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283472/),[h·μg] / [ml],9.88,155566,DB00583,L-Carnitine
,15283472,time (,"After oral administration of a 500 mg ALC tablet to 8 healthy volunteers, the principle pharmacokinetic parameters were 4.2 h of the half-life (t(1/2,beta)), the area under the curve (AUC(0-8)) of 9.88 microg.h/mL, and 3.1 h of the time (Tmax) to reach Cmax.",HPLC determination and pharmacokinetics of endogenous acetyl-L-carnitine (ALC) in human volunteers orally administered a single dose of ALC. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283472/),h,3.1,155567,DB00583,L-Carnitine
,15283472,Tmax),"After oral administration of a 500 mg ALC tablet to 8 healthy volunteers, the principle pharmacokinetic parameters were 4.2 h of the half-life (t(1/2,beta)), the area under the curve (AUC(0-8)) of 9.88 microg.h/mL, and 3.1 h of the time (Tmax) to reach Cmax.",HPLC determination and pharmacokinetics of endogenous acetyl-L-carnitine (ALC) in human volunteers orally administered a single dose of ALC. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283472/),h,3.1,155568,DB00583,L-Carnitine
>,32104361,recovery,"In this study, gradient elution with small particles size solid phase was applied to effectively separate gemcitabine and JDR, and protein precipitation pretreatment was adopted to remove plasma protein and extract the analytes with high recovery(>81%).",Development and validation of a UPLC-MS/MS assay for the determination of gemcitabine and its L-carnitine ester derivative in rat plasma and its application in oral pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104361/),%,81,157131,DB00583,L-Carnitine
,3234464,t1/2 beta of the elimination phase (beta),"Comparing the 2-g and 6-g doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant was 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.1 1 x h-1 (p less than 0.025), thus showing dose-related elimination.",Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234464/),h,6.5,164263,DB00583,L-Carnitine
,3234464,t1/2 beta of the elimination phase (beta),"Comparing the 2-g and 6-g doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant was 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.1 1 x h-1 (p less than 0.025), thus showing dose-related elimination.",Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234464/),h,3.9,164264,DB00583,L-Carnitine
,3234464,elimination constant,"Comparing the 2-g and 6-g doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant was 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.1 1 x h-1 (p less than 0.025), thus showing dose-related elimination.",Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234464/),1/[h],0.40,164265,DB00583,L-Carnitine
,3234464,elimination constant,"Comparing the 2-g and 6-g doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant was 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.1 1 x h-1 (p less than 0.025), thus showing dose-related elimination.",Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234464/),1/[h],0.50,164266,DB00583,L-Carnitine
,3234464,plasma carnitine clearance,"Comparing the 2-g and 6-g doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant was 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.1 1 x h-1 (p less than 0.025), thus showing dose-related elimination.",Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234464/),[1] / [h],5.4,164267,DB00583,L-Carnitine
,3234464,plasma carnitine clearance,"Comparing the 2-g and 6-g doses, the t1/2 beta of the elimination phase (beta) was 6.5 h vs 3.9 h, the elimination constant was 0.40 vs 0.50 h-1 and the plasma carnitine clearance was 5.4 vs 6.1 1 x h-1 (p less than 0.025), thus showing dose-related elimination.",Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234464/),[1] / [h],6.1,164268,DB00583,L-Carnitine
,3234464,Urinary recoveries,"Urinary recoveries after the 2-g and 6-g doses were 70% and 82% during the first 24 h, respectively.",Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234464/),%,70,164269,DB00583,L-Carnitine
,3234464,Urinary recoveries,"Urinary recoveries after the 2-g and 6-g doses were 70% and 82% during the first 24 h, respectively.",Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234464/),%,82,164270,DB00583,L-Carnitine
,3234464,Urinary recoveries,Urinary recoveries were 8% and 4% for the 2-g and 6-g doses during the first 24 h.,Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234464/),%,8,164271,DB00583,L-Carnitine
,3234464,Urinary recoveries,Urinary recoveries were 8% and 4% for the 2-g and 6-g doses during the first 24 h.,Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234464/),%,4,164272,DB00583,L-Carnitine
,3234464,oral bioavailability,The oral bioavailability of the 2-g dose was 16% and of the 6 h dose 5%.,Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234464/),%,16,164273,DB00583,L-Carnitine
,3234464,oral bioavailability,The oral bioavailability of the 2-g dose was 16% and of the 6 h dose 5%.,Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234464/),%,5,164274,DB00583,L-Carnitine
,9376826,t12,"Three methods were examined for labelling PLC in its propionyl group with positron-emitting carbon-11 (t12 = 20.3 min), one chemical and two chemoenzymatic.",Automated chemoenzymatic synthesis of no-carrier-added [carbonyl-11C]propionyl L-carnitine for pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9376826/),min,20.3,167907,DB00583,L-Carnitine
,9420036,maximum concentrations,"The maximum concentrations of R-95867 in serum (C[max]s) after the administration of CS-834 at doses of 50, 100, 200, and 400 mg were 0.51, 0.97, 1.59, and 2.51 microg/ml, respectively.","Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420036/),[μg] / [ml],0.51,178729,DB00583,L-Carnitine
,9420036,maximum concentrations,"The maximum concentrations of R-95867 in serum (C[max]s) after the administration of CS-834 at doses of 50, 100, 200, and 400 mg were 0.51, 0.97, 1.59, and 2.51 microg/ml, respectively.","Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420036/),[μg] / [ml],0.97,178730,DB00583,L-Carnitine
,9420036,maximum concentrations,"The maximum concentrations of R-95867 in serum (C[max]s) after the administration of CS-834 at doses of 50, 100, 200, and 400 mg were 0.51, 0.97, 1.59, and 2.51 microg/ml, respectively.","Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420036/),[μg] / [ml],1.59,178731,DB00583,L-Carnitine
,9420036,maximum concentrations,"The maximum concentrations of R-95867 in serum (C[max]s) after the administration of CS-834 at doses of 50, 100, 200, and 400 mg were 0.51, 0.97, 1.59, and 2.51 microg/ml, respectively.","Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420036/),[μg] / [ml],2.51,178732,DB00583,L-Carnitine
,9420036,half-lives (t1/2s),"The half-lives (t1/2s) were almost constant, approximately 0.7 h.","Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420036/),h,0.7,178733,DB00583,L-Carnitine
,9420036,cumulative recoveries,The cumulative recoveries in urine were approximately 30 to 35% until 24 h after drug administration.,"Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420036/),%,30 to 35,178734,DB00583,L-Carnitine
,16931611,relative bioavailability,Concentrations at week 1 (100.1 +/- 27.9) were not different (p = .19) from week 8 (78.6 +/- 29.3); an estimate of relative bioavailability was 78.6%.,Relative bioavailability of carnitine supplementation in premature neonates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16931611/),%,78.6,182089,DB00583,L-Carnitine
,16931611,Bioavailability,Bioavailability with paired analysis of neonates (n = 5) receiving 100% parenteral carnitine at week 1 and 100% enteral carnitine at week 8 was 83.7% +/- 41.2% (30.1%-140.6%).,Relative bioavailability of carnitine supplementation in premature neonates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16931611/),%,83.7,182090,DB00583,L-Carnitine
,7658356,absolute bioavailabilities,"Mean absolute bioavailabilities (based on free or total L-carnitine plasma concentrations) on Day 4 (fraction of the dose absorbed) of Carnitor (levocarnitine) tablet, Carnitor (levocarnitine) oral solution, and levocarnitine chewable tablet relative to the first iv dose were approximately 18%.",Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330-mg tablet versus 1-g chewable tablet versus enteral solution in healthy adult male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658356/),%,18,183943,DB00583,L-Carnitine
,7658356,absolute bioavailability,"Similarly, absolute bioavailability compared with the last iv dose was approximately 18% for all three oral formulations.",Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330-mg tablet versus 1-g chewable tablet versus enteral solution in healthy adult male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658356/),%,18,183944,DB00583,L-Carnitine
,16012283,peak levels,VPA peak levels ranged from 520 to 1700 mg/L with a mean of 1127 mg/L.,"Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012283/),[mg] / [l],1127,185472,DB00583,L-Carnitine
,32306775,drug loading capacity,"The modified polymeric micelles showed regular spherical shapes with small particle size of 157.1 ± 5.2 nm and high drug loading capacity of 15.96 ± 0.20 wt%, and the micelle stability in water was supported by low critical micelle concentration of 14.31 ± 0.21 μg/ml.",l-Carnitine conjugated chitosan-stearic acid polymeric micelles for improving the oral bioavailability of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32306775/),wt%,15.96,185904,DB00583,L-Carnitine
,32306775,critical micelle concentration,"The modified polymeric micelles showed regular spherical shapes with small particle size of 157.1 ± 5.2 nm and high drug loading capacity of 15.96 ± 0.20 wt%, and the micelle stability in water was supported by low critical micelle concentration of 14.31 ± 0.21 μg/ml.",l-Carnitine conjugated chitosan-stearic acid polymeric micelles for improving the oral bioavailability of paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32306775/),[μg] / [ml],14.31,185905,DB00583,L-Carnitine
,32306775,relative bioavailability,"The drug-loaded micelles presented a slow and incomplete in vitro release, and the pharmacokinetic studies indicated the micelle carriers increased the relative bioavailability of PTX to 165.8% against the commercial formulation.",l-Carnitine conjugated chitosan-stearic acid polymeric micelles for improving the oral bioavailability of paclitaxel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32306775/),%,165.8,185906,DB00583,L-Carnitine
,3276734,half-life,The half-life of plasma carnitine for cystinotic children given a single oral dose approximated 6.3 h; 14% of ingested L-carnitine was excreted within 24 h.,Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3276734/),h,6.3,186582,DB00583,L-Carnitine
,7492083,half-life,"The radioactivity was eliminated rapidly, with a half-life of approximately 3 h until 24 h at both the 6.65- and 26.6-mg/kg doses.","Disposition of S-1108, a new oral cephem antibiotic, and metabolic fate of pivalic acid liberated from [pivaloyl-14C]S-1108 in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7492083/),h,3,188805,DB00583,L-Carnitine
,11014405,extraction ratios,"Under baseline conditions the extraction ratios of L-carnitine and acetyl-L-carnitine by the dialyser were 0.74 +/- 0.07 and 0.71 +/- 0.11, respectively.",Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014405/),,0.74,190146,DB00583,L-Carnitine
,11014405,extraction ratios,"Under baseline conditions the extraction ratios of L-carnitine and acetyl-L-carnitine by the dialyser were 0.74 +/- 0.07 and 0.71 +/- 0.11, respectively.",Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014405/),,0.71,190147,DB00583,L-Carnitine
,17506778,volume of the central compartment,"Based on pooled data (mean +/- SD; n = 12), the volume of the central compartment was 10.09 +/- 0.72 l and the transfer rate constants into and out of the slowly equilibrating pool were 0.100 +/- 0.018 h(-1) and 0.00014 +/- 0.00016 h(-1), respectively.",A pharmacokinetic model for L-carnitine in patients receiving haemodialysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17506778/),l,10.09,191177,DB00583,L-Carnitine
,17506778,transfer rate constants,"Based on pooled data (mean +/- SD; n = 12), the volume of the central compartment was 10.09 +/- 0.72 l and the transfer rate constants into and out of the slowly equilibrating pool were 0.100 +/- 0.018 h(-1) and 0.00014 +/- 0.00016 h(-1), respectively.",A pharmacokinetic model for L-carnitine in patients receiving haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17506778/),1/[h],0.100,191178,DB00583,L-Carnitine
,17506778,transfer rate constants,"Based on pooled data (mean +/- SD; n = 12), the volume of the central compartment was 10.09 +/- 0.72 l and the transfer rate constants into and out of the slowly equilibrating pool were 0.100 +/- 0.018 h(-1) and 0.00014 +/- 0.00016 h(-1), respectively.",A pharmacokinetic model for L-carnitine in patients receiving haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17506778/),1/[h],0.00014,191179,DB00583,L-Carnitine
,17506778,turnover time,The turnover time of L-carnitine in the slow pool (which was assumed to represent muscle) was approximately 300 days.,A pharmacokinetic model for L-carnitine in patients receiving haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17506778/),d,300,191180,DB00583,L-Carnitine
,10087008,oral bioavailability,The oral bioavailability of L-[3H]carnitine in JVS mice (0.341) was about half of that in normal mice (0.675).,Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10087008/),,0.341,192129,DB00583,L-Carnitine
,10087008,oral bioavailability,The oral bioavailability of L-[3H]carnitine in JVS mice (0.341) was about half of that in normal mice (0.675).,Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10087008/),,0.675,192130,DB00583,L-Carnitine
,10087008,total clearance,"The cumulative urinary excretion of total radioactive carnitine in JVS mice was about 10-fold more than that in normal mice, and the total clearance of unchanged L-[3H]carnitine for JVS mice (6.70 ml/min) was significantly higher than that for normal mice (2.45 ml/min).",Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10087008/),[ml] / [min],6.70,192131,DB00583,L-Carnitine
,10087008,total clearance,"The cumulative urinary excretion of total radioactive carnitine in JVS mice was about 10-fold more than that in normal mice, and the total clearance of unchanged L-[3H]carnitine for JVS mice (6.70 ml/min) was significantly higher than that for normal mice (2.45 ml/min).",Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10087008/),[ml] / [min],2.45,192132,DB00583,L-Carnitine
,10087008,distribution volume at the steady state,The distribution volume at the steady state of unchanged L-[3H]carnitine in JVS mice (1.10 liters/kg) was significantly smaller than that in normal mice (8.16 liters/kg).,Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10087008/),[l] / [kg],1.10,192133,DB00583,L-Carnitine
,10087008,distribution volume at the steady state,The distribution volume at the steady state of unchanged L-[3H]carnitine in JVS mice (1.10 liters/kg) was significantly smaller than that in normal mice (8.16 liters/kg).,Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10087008/),[l] / [kg],8.16,192134,DB00583,L-Carnitine
,26248695,ch,The method had a chromatographic run time of 3.8 min and a linear calibration curve over the range 0.5-50 µg/mL (r > 0.99).,Assessment of pharmacokinetic interaction between piracetam and l-carnitine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248695/),min,3.8,192453,DB00583,L-Carnitine
,26248695,run time,The method had a chromatographic run time of 3.8 min and a linear calibration curve over the range 0.5-50 µg/mL (r > 0.99).,Assessment of pharmacokinetic interaction between piracetam and l-carnitine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248695/),min,3.8,192454,DB00583,L-Carnitine
,16172454,half-life,"Aplidine displayed a long half-life (21 to 44 hours), low clearance (45 to 49 L/h), and a high volume of distribution (1,036 to 1,124 L) with high interpatient variability in plasma, whereas in whole blood, clearance ranged from 3.0 to 6.2 L/h.","Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172454/),h,21 to 44,213898,DB00583,L-Carnitine
,16172454,clearance,"Aplidine displayed a long half-life (21 to 44 hours), low clearance (45 to 49 L/h), and a high volume of distribution (1,036 to 1,124 L) with high interpatient variability in plasma, whereas in whole blood, clearance ranged from 3.0 to 6.2 L/h.","Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172454/),[l] / [h],45 to 49,213899,DB00583,L-Carnitine
,16172454,volume of distribution,"Aplidine displayed a long half-life (21 to 44 hours), low clearance (45 to 49 L/h), and a high volume of distribution (1,036 to 1,124 L) with high interpatient variability in plasma, whereas in whole blood, clearance ranged from 3.0 to 6.2 L/h.","Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172454/),l,"1,036 to 1,124",213900,DB00583,L-Carnitine
,16172454,clearance,"Aplidine displayed a long half-life (21 to 44 hours), low clearance (45 to 49 L/h), and a high volume of distribution (1,036 to 1,124 L) with high interpatient variability in plasma, whereas in whole blood, clearance ranged from 3.0 to 6.2 L/h.","Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172454/),[l] / [h],3.0 to 6.2,213901,DB00583,L-Carnitine
,12908852,absolute bioavailability,"After oral doses of 1-6g, the absolute bioavailability is 5-18%.",Pharmacokinetics of L-carnitine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12908852/),%,5-18,222786,DB00583,L-Carnitine
,12908852,bioavailability,"In contrast, the bioavailability of dietary L-carnitine may be as high as 75%.",Pharmacokinetics of L-carnitine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12908852/),%,75,222787,DB00583,L-Carnitine
,12908852,initial distribution volume,"After intravenous administration, the initial distribution volume of L-carnitine is typically about 0.2-0.3 L/kg, which corresponds to extracellular fluid volume.",Pharmacokinetics of L-carnitine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12908852/),[l] / [kg],0.2-0.3,222788,DB00583,L-Carnitine
,12908852,renal clearance,"Under baseline conditions, the renal clearance of L-carnitine (1-3 mL/min) is substantially less than glomerular filtration rate (GFR), indicating extensive (98-99%) tubular reabsorption.",Pharmacokinetics of L-carnitine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12908852/),[ml] / [min],1-3,222789,DB00583,L-Carnitine
,9856404,Plasma ammonia N,"Plasma ammonia N was highest (P<.0001) in the UREA treatment compared with the CONT, CARN, and CARN + UREA treatments (148 vs 95, 101, and 108 micromol/L, respectively).",Influence of intravenous L-carnitine administration in sheep preceding an oral urea drench. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856404/),[μM] / [l],148,231497,DB00583,L-Carnitine
,9856404,Plasma ammonia N,"Plasma ammonia N was highest (P<.0001) in the UREA treatment compared with the CONT, CARN, and CARN + UREA treatments (148 vs 95, 101, and 108 micromol/L, respectively).",Influence of intravenous L-carnitine administration in sheep preceding an oral urea drench. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856404/),[μM] / [l],95,231498,DB00583,L-Carnitine
,9856404,Plasma ammonia N,"Plasma ammonia N was highest (P<.0001) in the UREA treatment compared with the CONT, CARN, and CARN + UREA treatments (148 vs 95, 101, and 108 micromol/L, respectively).",Influence of intravenous L-carnitine administration in sheep preceding an oral urea drench. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856404/),[μM] / [l],101,231499,DB00583,L-Carnitine
,9856404,Plasma ammonia N,"Plasma ammonia N was highest (P<.0001) in the UREA treatment compared with the CONT, CARN, and CARN + UREA treatments (148 vs 95, 101, and 108 micromol/L, respectively).",Influence of intravenous L-carnitine administration in sheep preceding an oral urea drench. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856404/),[μM] / [l],108,231500,DB00583,L-Carnitine
,2333732,areas under,The areas under the testosterone- and dihydrotestosterone-curves did not differ significantly 2290 +/- 340 (dihydrotestosterone-enanthate) vs 2920 +/- 485 (testosterone-enanthate) suggesting that similar amounts of steroid had been released from the respective ester preparation.,Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333732/),,2290,237195,DB00583,L-Carnitine
,2333732,areas under,The areas under the testosterone- and dihydrotestosterone-curves did not differ significantly 2290 +/- 340 (dihydrotestosterone-enanthate) vs 2920 +/- 485 (testosterone-enanthate) suggesting that similar amounts of steroid had been released from the respective ester preparation.,Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333732/),,2920,237196,DB00583,L-Carnitine
,2333732,half-life,"Mean half-life estimates of the terminal elimination phase were 4 and 7 days for testosterone-enanthate and dihydrotestosterone-enanthate, respectively.",Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333732/),d,4,237197,DB00583,L-Carnitine
,2333732,half-life,"Mean half-life estimates of the terminal elimination phase were 4 and 7 days for testosterone-enanthate and dihydrotestosterone-enanthate, respectively.",Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333732/),d,7,237198,DB00583,L-Carnitine
,2333732,half-life,"Mean half-life estimates for testosterone-enanthate and dihydrotestosterone were 5 and 7 days, respectively.",Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333732/),d,5,237199,DB00583,L-Carnitine
,2333732,half-life,"Mean half-life estimates for testosterone-enanthate and dihydrotestosterone were 5 and 7 days, respectively.",Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333732/),d,7,237200,DB00583,L-Carnitine
,21056096,maximal concentration (Cmax),"Following sodium caprate pre-treatment, ropivacaine intrathecal maximal concentration (Cmax) was 1.6 times higher (78 ± 16 μg ml(-1) vs 129 ± 26 μg ml(-1), p<0.05) but the influence of the absorption enhancer was only effective the first 30 min following ropivacaine injection, as seen with the significantly increase of intrathecal AUC(0-30 min) (1629 ± 437 μg min ml(-1) vs 2477 ± 559 μg min ml(-1), p<0.05) resulting in a bioavailable fraction 130% higher 30 min after ropivavaine administration.",Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056096/),[μg] / [ml],78,237657,DB00583,L-Carnitine
,21056096,maximal concentration (Cmax),"Following sodium caprate pre-treatment, ropivacaine intrathecal maximal concentration (Cmax) was 1.6 times higher (78 ± 16 μg ml(-1) vs 129 ± 26 μg ml(-1), p<0.05) but the influence of the absorption enhancer was only effective the first 30 min following ropivacaine injection, as seen with the significantly increase of intrathecal AUC(0-30 min) (1629 ± 437 μg min ml(-1) vs 2477 ± 559 μg min ml(-1), p<0.05) resulting in a bioavailable fraction 130% higher 30 min after ropivavaine administration.",Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056096/),[μg] / [ml],129,237658,DB00583,L-Carnitine
,21056096,AUC(0-30 min),"Following sodium caprate pre-treatment, ropivacaine intrathecal maximal concentration (Cmax) was 1.6 times higher (78 ± 16 μg ml(-1) vs 129 ± 26 μg ml(-1), p<0.05) but the influence of the absorption enhancer was only effective the first 30 min following ropivacaine injection, as seen with the significantly increase of intrathecal AUC(0-30 min) (1629 ± 437 μg min ml(-1) vs 2477 ± 559 μg min ml(-1), p<0.05) resulting in a bioavailable fraction 130% higher 30 min after ropivavaine administration.",Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056096/),[min·μg] / [ml],1629,237659,DB00583,L-Carnitine
,21056096,AUC(0-30 min),"Following sodium caprate pre-treatment, ropivacaine intrathecal maximal concentration (Cmax) was 1.6 times higher (78 ± 16 μg ml(-1) vs 129 ± 26 μg ml(-1), p<0.05) but the influence of the absorption enhancer was only effective the first 30 min following ropivacaine injection, as seen with the significantly increase of intrathecal AUC(0-30 min) (1629 ± 437 μg min ml(-1) vs 2477 ± 559 μg min ml(-1), p<0.05) resulting in a bioavailable fraction 130% higher 30 min after ropivavaine administration.",Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056096/),[min·μg] / [ml],2477,237660,DB00583,L-Carnitine
,21056096,bioavailable fraction,"Following sodium caprate pre-treatment, ropivacaine intrathecal maximal concentration (Cmax) was 1.6 times higher (78 ± 16 μg ml(-1) vs 129 ± 26 μg ml(-1), p<0.05) but the influence of the absorption enhancer was only effective the first 30 min following ropivacaine injection, as seen with the significantly increase of intrathecal AUC(0-30 min) (1629 ± 437 μg min ml(-1) vs 2477 ± 559 μg min ml(-1), p<0.05) resulting in a bioavailable fraction 130% higher 30 min after ropivavaine administration.",Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056096/),%,130,237661,DB00583,L-Carnitine
,21701126,maximum plasma concentration (C(max)),"After single oral administration, the maximum plasma concentration (C(max)) and area under the curve (AUC(0-∞)) were 84.7 ± 25.2 µmol/L and 2,676.4 ± 708.3 µmol/L·h, respectively.",Single dose administration of L-carnitine improves antioxidant activities in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21701126/),[μM] / [l],84.7,242391,DB00583,L-Carnitine
,21701126,area under the curve (AUC(0-∞)),"After single oral administration, the maximum plasma concentration (C(max)) and area under the curve (AUC(0-∞)) were 84.7 ± 25.2 µmol/L and 2,676.4 ± 708.3 µmol/L·h, respectively.",Single dose administration of L-carnitine improves antioxidant activities in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21701126/),[μM] / [h·l],"2,676.4",242392,DB00583,L-Carnitine
,21701126,half-life,"The half-life and the time required to reach the C(max) was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively.",Single dose administration of L-carnitine improves antioxidant activities in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21701126/),min,60.3,242393,DB00583,L-Carnitine
,21701126,time required to reach the C(max),"The half-life and the time required to reach the C(max) was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively.",Single dose administration of L-carnitine improves antioxidant activities in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21701126/),h,3.4,242394,DB00583,L-Carnitine
,8535330,t1/2,"The prospective therapeutic, propionyl-L-carnitine, was labelled in the N-methyl position with the positron-emitter, carbon-11 (t1/2 = 20.4 min), with a view to studying its pharmacokinetics in humans using PET.",Propionyl-L-carnitine: labelling in the N-methyl position with carbon-11 and pharmacokinetic studies in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8535330/),min,20.4,249084,DB00583,L-Carnitine
,17073580,clearances,"The hemodialysis clearances for L-carnitine, trimethylamine and trimethylamine-N-oxide were 14.3 +/- 8.2, 14.1 +/- 10.6 and 12.4 +/- 5.4 L/h, respectively, indicating their efficient removal by dialysis.",Oral L-carnitine: metabolite formation and hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17073580/),[l] / [h],14.3,253950,DB00583,L-Carnitine
,17073580,clearances,"The hemodialysis clearances for L-carnitine, trimethylamine and trimethylamine-N-oxide were 14.3 +/- 8.2, 14.1 +/- 10.6 and 12.4 +/- 5.4 L/h, respectively, indicating their efficient removal by dialysis.",Oral L-carnitine: metabolite formation and hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17073580/),[l] / [h],14.1,253951,DB00583,L-Carnitine
,17073580,clearances,"The hemodialysis clearances for L-carnitine, trimethylamine and trimethylamine-N-oxide were 14.3 +/- 8.2, 14.1 +/- 10.6 and 12.4 +/- 5.4 L/h, respectively, indicating their efficient removal by dialysis.",Oral L-carnitine: metabolite formation and hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17073580/),[l] / [h],12.4,253952,DB00583,L-Carnitine
,15591001,Bioavailability,Bioavailability of dietary L-carnitine is 54-87% and is dependent on the amount of L-carnitine in the meal.,"Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15591001/),%,54-87,256772,DB00583,L-Carnitine
,15591001,bioavailability,Absorption of L-carnitine dietary supplements (0.5-6 g) is primarily passive; bioavailability is 14-18% of dose.,"Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15591001/),%,14-18,256773,DB00583,L-Carnitine
,15591001,whole-body turnover time,"At normal dietary L-carnitine intake, whole-body turnover time in humans is 38-119 h.","Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15591001/),h,38-119,256774,DB00583,L-Carnitine
,15591001,clearance,"At normal circulating l-carnitine concentrations, renal l-carnitine reabsorption is highly efficient (90-99% of filtered load; clearance, 1-3 mL/min), but displays saturation kinetics.","Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15591001/),[ml] / [min],1-3,256775,DB00583,L-Carnitine
,20348051,plasmatic concentration,"An acidosis (pH = 7.24), a hyperlactatemia (2.72 mmol/L), a hyperammonemia (328.9 micromol/L), and were diagnosed valproic acid plasmatic concentration was 1190 microg/mL at 22 hours.",[Pharmacokinetics of biological tags in a case of acute valpromide self poisoning]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20348051/),,1190,260965,DB00583,L-Carnitine
,8310709,excretion,"2. A 22-fold increase occurred in urinary carnitine ester excretion on the last day of treatment (2967 +/- 604 versus 134 +/- 50 mumol/day, p < 0.05); the pivaloylcarnitine was identified with 13C-n.m.r.",Preferential elimination of pivalate with supplemental carnitine via formation of pivaloylcarnitine in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310709/),[μM] / [d],2967,265803,DB00583,L-Carnitine
,8310709,excretion,"2. A 22-fold increase occurred in urinary carnitine ester excretion on the last day of treatment (2967 +/- 604 versus 134 +/- 50 mumol/day, p < 0.05); the pivaloylcarnitine was identified with 13C-n.m.r.",Preferential elimination of pivalate with supplemental carnitine via formation of pivaloylcarnitine in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310709/),[μM] / [d],134,265804,DB00583,L-Carnitine
,29237296,maximal concentration,"Using 60mg as an example, the maximal concentration of LB80331 in plasma is 397 ng/mL.",Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237296/),[ng] / [ml],397,267747,DB00583,L-Carnitine
,29237296,time required to reach maximal concentration,"The time required to reach maximal concentration in plasma and elimination half-life are 2.0 and 3.0 h, respectively.",Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237296/),h,2.0,267748,DB00583,L-Carnitine
,29237296,time required to reach maximal concentration,"The time required to reach maximal concentration in plasma and elimination half-life are 2.0 and 3.0 h, respectively.",Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237296/),h,3.0,267749,DB00583,L-Carnitine
,29237296,elimination half-life,"The time required to reach maximal concentration in plasma and elimination half-life are 2.0 and 3.0 h, respectively.",Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237296/),h,2.0,267750,DB00583,L-Carnitine
,29237296,elimination half-life,"The time required to reach maximal concentration in plasma and elimination half-life are 2.0 and 3.0 h, respectively.",Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237296/),h,3.0,267751,DB00583,L-Carnitine
